SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR

Category Primary study
JournalAnnals of the Rheumatic Diseases
Year 2023
This article has no abstract
Epistemonikos ID: 15420de34404625097bc0c040240251331bbcf01
First added on: Dec 07, 2023